肺癌患者血浆Fas水平的检测及临床意义

The level of plasma-soluble Fas and its clinical value in patients with lung carcinoma

目的 探讨肺癌患者血浆Fas测定的临床价值。方法 采用酶联免疫吸附试验(ELISA)检测 6 0例肺癌患者血浆Fas水平 ,应用双抗体免疫荧光剂、采用流式细胞仪 (FACS)测定肺癌患者T淋巴细胞亚群 ,分析其临床价值。结果 40 %患者血浆Fas水平升高 ,血浆Fas水平与病理类型无关 ,受临床分期的影响 ,进展期显著高于早期患者 (P <0 0 5 ) ,进展期CD+3 、HLA DR+细胞及CD+1 6、CD+56细胞比例亦显著高于早期患者 ,其CD+4 、CD-8细胞比例显著低于早期患者。初诊时血浆Fas升高的小细胞肺癌患者疗效较好。治疗后有效、病情稳定的患者 ,血浆Fas水平降至正常。结论 肺癌患者血浆Fas水平显著升高 ,并与患者T细胞亚群有关 。

Objective To explore the clinical value of plasma soluble Fas(Fas)in patients with lung carcinoma Methods Plasma Fas level was measured by ELISA method T lymphocyte phenotype was analysed by flow cytometry in 60 patients with lung cancer Results The level of Fas was higher in 40% patients There was no relationship between level of Fas and pathology But level of Fas was associated with clinical stage, there was higher level of Fas in patients with advanced neoplastic disease than early stage The frequencies of activated T cells (CD + 3,HLA DR +)and NK cells (CD + 16 , CD + 56 )were also significantly increased in advanced neoplastic patients However, there was a significant decrease in helper T cells (CD + 4, CD - 8) in advanced patients Primary diagnosed SCLC patients with elevated Fas often had good responses to chemotherapy Plasma Fas level decreased to normal through effective therapy Conclusions There is a elevated plasma Fas level in patients with lung cancer It is associated with lymphocyte phenotype Plasma Fas may be used as a useful parameter in predicting response to therapy or disease activity